$NVLX Readies for Late-Stage Trials as NCI Seeks New

New Post Public Reply Private Reply Replies (1) Message Board
PYCKtradr PYCKtradr #20241

$NVLX Readies for Late-Stage Trials as NCI Seeks New Pancreatic Cancer Drugs

National Cancer Institute Seeking a New Pancreatic Cancer Treatment as Death Rates Rise

December 20, 2013 /

There may be a more optimistic future on the horizon for those afflicted by pancreatic cancer. Currently, Eli Lilly’s (LLY) Gemzar® (gemcitabine) is the only single?agent FDA ? approved (in 1996) drug to treat the disease that a November article in the Journal of the National Cancer Institute stated will become the number two cause of cancer deaths in the next decade. In September, the FDA approved Celgene’s (CELG) Abraxane®, a nanoparticle formulation of albumin with the widely used anticancer drug paclitaxel (Taxol®), in combination with gemcitabine. Major reasons for the FDA approval of the Abraxane® plus gemcitabine combination included a median survival time of 8.5 months as compared to 6.7 months for gemcitabine alone and a one?year survival rate that was increased by 59% over that seen with gemcitabine alone. Shares of Celgene have more than doubled in 2013 to $170, in part because of the approval of the Abraxane/gemcitabine combination.


What if there’s something even better than Gemzar® (gemcitabine) or Abraxane + gemcitabine?

Nuvilex, Inc. (NVLX) may be bringing that caliber of a therapeutic down its pipeline with its treatment for pancreatic cancer that is composed of the well?known anti?cancer prodrug ifosfamide and the cellulose?based, live?cell encapsulation technology for a variety of hard?to?treat diseases, such as cancer and diabetes. As a prodrug, ifosfamide must be converted (activated) into its cancer killing form before it is effective. The cell encapsulation technology, called “Cell?in?a?Box™,” is a novel platform that puts ifosfamide?activating cells into pin?head?sized, spherical capsules that are then implanted into patients with advanced, inoperable pancreatic cancer, near the pancreas and therefore the tumor itself. By activating the anti?cancer drug very near the tumor, the cancer?killing effects of the ifosfamide are optimized.

In Phase 1/2 clinical trials using the Cell?in?a?Box™/ifosfamide combination treatment, when the results were compared with those from pivotal studies used by the FDA to approve Gemzar®, the Cell? in?a?Box™/ifosfamide combination gave a median survival time of 11 months as compared to 5.7 months for Gemzar® and a one?year survival rate (36%) that was double that seen with Gemzar®. By comparison, as noted above, in the pivotal trial that led to the approval of Celgene’s Abraxane®/gemcitabine combination, patients treated with that combination had a one?year survival rate that was 59% greater than that for gemcitabine and a median survival time of 8.5 months versus 6.7 months with gemcitabine alone.


If the above apparent superiority of the Cell?in?a?Box™/ifosfamide combination as compared to either Gemzar® or the Abraxane®/gemcitabine combination sounds amazing, that’s because it is, particularly if one realizes that, since 1996, only two treatments have been approved by the FDA for the treatment of advanced, inoperable pancreatic cancer with the latest and best being Celgene’s Abraxane®/gemcitabine combination.


But it even gets better. Whereas serious side effects were seen in patients receiving treatment with Gemzar® or the Abraxane®/gemcitabine combination, no serious side effects were seen in patients treated with the Cell?in?a?Box™/ifosfamide combination. This is because, patients in the Phase 1/2 trials with the latter combination were given ifosfamide at only one?third of the dose normally administered when this anti?cancer drug is used alone to treat cancers, whereas patients in the pivotal trials for Gemzar® or the Abraxane®/gemcitabine combination were given the highest doses that they could tolerate. The reduced side effect profile seen with the Cell?in?a?Box™/ifosfamide treatment resulted in an overall better “quality?of?life” for the patients.

Nuvilex is in the midst of preparing for late?stage trials to evaluate the Cell?in?a?Box™/ifosfamide combination directly against gemcitabine, similar to what Celgene just did. If the results replicate the Phase 1/2 data and outperform not only gemcitabine, but also the Abraxane®/gemcitabine combination, whil e at the same time reducing the side effects associated with the treatment of advanced, inoperable pancreatic cancer, the days of Nuvilex trading at 12 cents per share will be a distant memory. Savvy biotech investors know that the time to invest is before clinical data arrives in order to catch the full breadth of a move, particularly if positive top?line results are delivered, meaning that now, not later, is the time to be taking a close look at Nuvilex, Inc. (NVLX) and its acquisition of the rights to use a unique live?cell encapsulation technology that could revolutionize treatments for pancreatic cancer as well as other deadly diseases.


About Baystreet Media Group (BMG): BMG is a full service Investment Relations firm. For more information and to read disclaimers and disclosures: www.baystreetmediagroup.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Spruce Spins Adrenyx En Route to Nasdaq in 2027

Updated Category News Views 206

New Frontiers: Adrenyx Biosciences Takes Shape Well, here's a new chapter in biotech drama. Spruce Biosciences, a name you might have tangled with if you're into tickers like NASDAQ:SPRB, just carved out a niche with the birth of Adrenyx Biosciences. The play? A separate company eyeing the endocrinology space, setting its sights on tackling congenital adrenal hyperplasia...

Continue Reading
Linux Foundation Unveils the Global Fraud Alliance

Updated Category News Views 173

Who would have thought the tech wizards at the Linux Foundation would step up to tackle fraud on a global scale? That's what we've got with their latest play: the Open Financial Trust Alliance (OFTA). Launched at the Singapore FinTech Festival, they've got their sights on connecting the world's disconnected fraud fight. Think of it as a translator for the tangled mess of...

Continue Reading
Watson Motion Tests Military Pretrial Confinement Rules

Updated Category News Views 39

Military confinement fights are rarely neat, and this one comes with a short clock but plenty of unanswered questions. Defense lawyers for U.S. Air Force Maj. Jason Watson argued on Nov. 17 that he should be released from pretrial confinement while his case proceeds. A military judge is ordinarily expected to issue a ruling within 14 days of the hearing, under the court's...

Continue Reading
Chaos Zero Nightmare's Award Is a Useful Signal for Games

Updated Category News Views 232

A story award can be easy to sneer at until a live-service game earns one across three markets. Smilegate's Chaos Zero Nightmare, a dark fantasy roguelike RPG developed by Super Creative, was named Best Story in Google Play's Best of 2026 awards for Taiwan, Hong Kong and Macau. That is not a sales figure, not a profit disclosure, and certainly not proof that a hit has...

Continue Reading
Unilumin's APEC 2026 Showcase Is a Useful Field Test

Updated Category News Views 65

Few sales pitches get stress-tested by a thousand journalists, a major airport, and a leaders' summit all at once. That is the useful part of Unilumin's role as an official sponsor of APEC 2026 in Shenzhen. The company says its LED systems were installed across summit venues, the media center, transportation hubs, and city landmarks as the 33rd APEC Economic Leaders'...

Continue Reading
Yatsen’s November 25 Report Is the Real Beauty Test

Updated Category News Views 0

Beauty shelves can hide a lot of sins, but earnings day tends to drag them into fluorescent light. Yatsen will release unaudited third-quarter 2026 financial results before the U.S. market opens on Wednesday, November 25, then management will take questions at 7:30 a.m. Eastern Time. For anyone following NYSE:YSG, this is not a results story yet. It is a calendar marker,...

Continue Reading
LifeVac's 7,000 Reported Saves Deserve Careful Context

Updated Category News Views 216

Veggie straws are supposed to be harmless until they are not. LifeVac says a 19-month-old girl in South Dakota became unable to breathe on November 14 after eating the snack, with a sticky piece creating a complete airway obstruction. Her father retrieved the family's LifeVac, used the pediatric mask while she was on her back, and the company says one application...

Continue Reading
Unisys Opens Its 2027 Innovation Program Across India

Updated Category News Views 147

Talent pipelines rarely make the market’s pulse race, but they can expose whether a tech firm is still trying to build for the next turn. Unisys has opened registration for the 2027 Unisys Innovation Program, its eighteenth annual technical competition for engineering students in India. For a company selling cloud, AI, digital workplace, applications and enterprise...

Continue Reading
Sinopec’s Algerian Outreach Reveals a Patient Long Game

Updated Category News Views 0

Soft Power Does Not Run a Refinery, but It Matters A short video contest in Algiers will not move an oilfield schedule or settle a hydrocarbons negotiation. That is precisely why this Sinopec-backed event deserves a sober look rather than a chest-thumping one. On Nov. 15, Sinopec Group and the Chinese Embassy in Algeria co-hosted the final of their second youth cultural...

Continue Reading
MobileX's $10 Plan Puts Holiday Pressure on Wireless

Updated Category News Views 229

A sixty-dollar commitment is a small bet, but in wireless it can become a loud little nuisance for every carrier charging far more. MobileX has rolled out a Black Friday offer giving new customers 10GB of high-speed data, unlimited talk and text, and six months of service for $60 upfront. That pencils out to $10 a month, before taxes and government surcharges, and it runs...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding JD.com's Options Activity and Market Trends

Updated Category News Views 250

JD.com's Options Activity Overview Financial giants are making notable bullish moves regarding JD.com. Our detailed analysis of options history for JD.com (NASDAQ: JD) has identified several unusual trades that highlight prevailing market sentiments. Breakdown of Trader Sentiment A closer examination of the activity reveals that 60% of traders are bullish, while 40%...

Continue Reading
Wells Fargo Invests in Nuclear Energy Amid AI-Powered Demand Surge

Updated Category News Views 293

Wells Fargo's Strategic Bet on Nuclear Energy Wells Fargo Investment Institute is strategically investing in nuclear energy as a pivotal solution to drive the U.S. economy forward. This decision mirrors the positive outlook from various investment analysts and experts, who note escalating electricity demand. Anticipating a Surge in U.S. Power Demand The firm has recently...

Continue Reading
Costco to Expand with Four New Locations by End of 2024

Updated Category News Views 429

Costco's Future Expansion Plans If you love the incredible value that Costco provides, there's some exciting news ahead. The company is preparing to open four new warehouse locations across the U.S. by the end of this year. With their well-known selection of bulk products, even more shoppers will have the chance to enjoy these retail giants. New Location Details...

Continue Reading
Heineken 0.0 Campaign Challenges Social Stigmas on Drinking

Updated Category News Views 617

Heineken 0.0 Campaign Challenges Perceptions of Non-Alcoholic Choices In today's evolving society, drinking habits are undergoing significant transformation. The longstanding habits surrounding alcohol consumption are being reevaluated, inspiring brands like Heineken® to adapt their marketing strategies. A recent study indicated that despite the increasing popularity of...

Continue Reading
Revolutionizing Cancer Monitoring: DELFI Diagnostics' Innovations

Updated Category News Views 309

Revolutionizing Cancer Monitoring Technology at AACR Meeting DELFI Diagnostics, a pioneer in fragmentomics, is set to present innovative solutions for early cancer detection and treatment monitoring at a prominent oncology research event. Their advanced technologies, which leverage the analysis of cell-free DNA (cfDNA), promise to enhance both the screening process for...

Continue Reading